Secondary resistances emerging during treatment are a major problem in oncology. If tumour models can be characterised for their primary resistances to reference therapies, there is a lack of preclinical models for secondary resistances.
Antineo has developed preclinical tumour models resistant to reference immunotherapies from sensitive cells. We have a panel of CDX and syngeneic models which can be used either to assess the efficacy of compounds designed to be used in second line, or to revert the resistances.
To learn more about our original preclinical tumour models for secondary resistances, please contact us.